According to Lilly, antimicrobial resistance (AMR) poses a significant risk throughout the world, especially in low- and middle-income countries. "Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials and the development of custom, purpose-built technologies in the battle against drug-resistant pathogens. The partnership is part of Lilly’s initiative to fight drug-resistant pathogens through its Social Impact Venture Capital Portfolio. Antimicrobial resistance. Antimicrobial Resistance.

Source: ABC News June 26, 2024 22:16 UTC